Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465632 · ClinicalTrials.gov registry record · Phase 3
To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.
A Phase 3 study, sponsored by Glenmark Pharmaceuticals Ltd. India.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
NCT02465632 is a Phase 3 study that has completed, run by Glenmark Pharmaceuticals Ltd. India. The registered enrollment target is 1,100 participants.
The verdict
NCT02465632, a Phase 3 study, has completed, sponsored by Glenmark Pharmaceuticals Ltd. India.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl peroxide 5% (Valeant Pharmaceuticals, US) in the treatment of acne vulgaris.
Interventions
- DRUG Placebo
- DRUG Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel
- DRUG BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02465632
The ClinicalTrials.gov registry entry for NCT02465632 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glenmark Pharmaceuticals Ltd. India, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02465632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02465632 about?
NCT02465632 is a clinical study titled "To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.". This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the marketed product BenzaClin® Topical Gel, Clindamycin 1%/ Benzoyl perox...
What is the current status of trial NCT02465632?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2015-04. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02465632?
The interventions under investigation include: Placebo (DRUG), Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (DRUG), BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (DRUG).
Who is sponsoring clinical trial NCT02465632?
This trial is sponsored by Glenmark Pharmaceuticals Ltd. India, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.